Xin Lang Cai Jing·2025-11-25 07:13Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Company Overview - Haiprui is headquartered in Shenzhen, China, and was listed on May 6, 2010. Its main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The revenue composition of Haiprui is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounts for 93.04%, benefiting from the depreciation of the RMB [3]. - Haiprui has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 25, Haiprui's stock rose by 0.77%, with a trading volume of 37.2831 million yuan and a turnover rate of 0.25%, bringing the total market capitalization to 17.314 billion yuan [1]. - The stock has seen a net outflow of 1.3632 million yuan from major investors today, with a ranking of 113 out of 159 in the industry [4]. Technical Analysis - The average trading cost of Haiprui's shares is 11.59 yuan, with the stock price approaching a resistance level of 11.81 yuan, indicating potential for a price correction if it fails to break through this level [6].